JP2023182667A5 - - Google Patents

Download PDF

Info

Publication number
JP2023182667A5
JP2023182667A5 JP2023166306A JP2023166306A JP2023182667A5 JP 2023182667 A5 JP2023182667 A5 JP 2023182667A5 JP 2023166306 A JP2023166306 A JP 2023166306A JP 2023166306 A JP2023166306 A JP 2023166306A JP 2023182667 A5 JP2023182667 A5 JP 2023182667A5
Authority
JP
Japan
Prior art keywords
tapering
eltrombopag
pharmaceutical composition
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023166306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023182667A (ja
Filing date
Publication date
Priority claimed from JP2021568408A external-priority patent/JP2022537883A/ja
Application filed filed Critical
Priority to JP2023166306A priority Critical patent/JP2023182667A/ja
Publication of JP2023182667A publication Critical patent/JP2023182667A/ja
Publication of JP2023182667A5 publication Critical patent/JP2023182667A5/ja
Pending legal-status Critical Current

Links

JP2023166306A 2019-05-14 2023-09-27 エルトロンボパグの投与計画 Pending JP2023182667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023166306A JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021568408A JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
JP2023166306A JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021568408A Division JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画

Publications (2)

Publication Number Publication Date
JP2023182667A JP2023182667A (ja) 2023-12-26
JP2023182667A5 true JP2023182667A5 (cg-RX-API-DMAC7.html) 2024-05-16

Family

ID=67211802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568408A Withdrawn JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画
JP2023166306A Pending JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568408A Withdrawn JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Similar Documents

Publication Publication Date Title
JP2022509358A5 (cg-RX-API-DMAC7.html)
JP2009529502A5 (cg-RX-API-DMAC7.html)
JP2018513188A5 (cg-RX-API-DMAC7.html)
JP2018507243A5 (cg-RX-API-DMAC7.html)
CN103298464A (zh) 复方组合物
JP2015172060A5 (cg-RX-API-DMAC7.html)
JP2023526754A5 (cg-RX-API-DMAC7.html)
JP2022548575A5 (cg-RX-API-DMAC7.html)
JP2025148449A5 (cg-RX-API-DMAC7.html)
Thomas et al. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2023546503A5 (cg-RX-API-DMAC7.html)
Moe et al. High dose methotrexate in acute lymphocytic leukemia in childhood
JP2021152002A5 (cg-RX-API-DMAC7.html)
JP2011506607A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2018529747A5 (cg-RX-API-DMAC7.html)
JP2022547061A5 (cg-RX-API-DMAC7.html)
Tachdjian et al. Donidalorsen for hereditary angioedema: results from the OASISplus open-label extension study
JP2022538898A5 (cg-RX-API-DMAC7.html)
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2025521501A5 (cg-RX-API-DMAC7.html)
JP2021091608A5 (cg-RX-API-DMAC7.html)
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法